nodes	percent_of_prediction	percent_of_DWPC	metapath
Didanosine—Amylase increased—Sorafenib—liver cancer	0.0425	0.0452	CcSEcCtD
Didanosine—PNP—Daunorubicin—Epirubicin—liver cancer	0.031	0.519	CbGdCrCtD
Didanosine—Lactic acidosis—Epirubicin—liver cancer	0.0307	0.0326	CcSEcCtD
Didanosine—PNP—Daunorubicin—Doxorubicin—liver cancer	0.0287	0.48	CbGdCrCtD
Didanosine—Lactic acidosis—Doxorubicin—liver cancer	0.0284	0.0302	CcSEcCtD
Didanosine—Rhabdomyolysis—Sorafenib—liver cancer	0.0229	0.0243	CcSEcCtD
Didanosine—Drug interaction—Sorafenib—liver cancer	0.0218	0.0232	CcSEcCtD
Didanosine—Neuropathy—Sorafenib—liver cancer	0.019	0.0202	CcSEcCtD
Didanosine—Leukoderma—Epirubicin—liver cancer	0.0176	0.0187	CcSEcCtD
Didanosine—Hepatic function abnormal—Sorafenib—liver cancer	0.0168	0.0179	CcSEcCtD
Didanosine—Hepatic failure—Sorafenib—liver cancer	0.0164	0.0174	CcSEcCtD
Didanosine—Leukoderma—Doxorubicin—liver cancer	0.0163	0.0173	CcSEcCtD
Didanosine—Renal failure acute—Sorafenib—liver cancer	0.0159	0.0169	CcSEcCtD
Didanosine—Abdominal pain upper—Sorafenib—liver cancer	0.0134	0.0143	CcSEcCtD
Didanosine—Pancreatitis—Sorafenib—liver cancer	0.0125	0.0132	CcSEcCtD
Didanosine—Optic neuritis—Epirubicin—liver cancer	0.0122	0.0129	CcSEcCtD
Didanosine—Optic neuritis—Doxorubicin—liver cancer	0.0113	0.012	CcSEcCtD
Didanosine—Neuropathy peripheral—Sorafenib—liver cancer	0.0111	0.0118	CcSEcCtD
Didanosine—Hepatobiliary disease—Sorafenib—liver cancer	0.0107	0.0114	CcSEcCtD
Didanosine—Hepatomegaly—Epirubicin—liver cancer	0.0106	0.0112	CcSEcCtD
Didanosine—Neuritis—Epirubicin—liver cancer	0.01	0.0107	CcSEcCtD
Didanosine—Hepatomegaly—Doxorubicin—liver cancer	0.00978	0.0104	CcSEcCtD
Didanosine—Neuritis—Doxorubicin—liver cancer	0.00928	0.00986	CcSEcCtD
Didanosine—Alopecia—Sorafenib—liver cancer	0.00899	0.00956	CcSEcCtD
Didanosine—Blood disorder—Epirubicin—liver cancer	0.00896	0.00953	CcSEcCtD
Didanosine—Liver injury—Epirubicin—liver cancer	0.00889	0.00946	CcSEcCtD
Didanosine—Blood disorder—Doxorubicin—liver cancer	0.00829	0.00882	CcSEcCtD
Didanosine—Liver injury—Doxorubicin—liver cancer	0.00823	0.00875	CcSEcCtD
Didanosine—Anaemia—Sorafenib—liver cancer	0.00818	0.0087	CcSEcCtD
Didanosine—Hyperuricaemia—Epirubicin—liver cancer	0.00807	0.00858	CcSEcCtD
Didanosine—Leukopenia—Sorafenib—liver cancer	0.00792	0.00843	CcSEcCtD
Didanosine—Inflammation—Epirubicin—liver cancer	0.00772	0.0082	CcSEcCtD
Didanosine—Blood uric acid increased—Epirubicin—liver cancer	0.00762	0.0081	CcSEcCtD
Didanosine—Arthralgia—Sorafenib—liver cancer	0.00754	0.00801	CcSEcCtD
Didanosine—Myalgia—Sorafenib—liver cancer	0.00754	0.00801	CcSEcCtD
Didanosine—Hepatocellular injury—Epirubicin—liver cancer	0.00748	0.00796	CcSEcCtD
Didanosine—Hyperuricaemia—Doxorubicin—liver cancer	0.00746	0.00794	CcSEcCtD
Didanosine—Dry mouth—Sorafenib—liver cancer	0.00737	0.00784	CcSEcCtD
Didanosine—Anaphylactic shock—Sorafenib—liver cancer	0.00722	0.00768	CcSEcCtD
Didanosine—Infection—Sorafenib—liver cancer	0.00718	0.00763	CcSEcCtD
Didanosine—Inflammation—Doxorubicin—liver cancer	0.00714	0.00759	CcSEcCtD
Didanosine—Thrombocytopenia—Sorafenib—liver cancer	0.00707	0.00752	CcSEcCtD
Didanosine—Blood uric acid increased—Doxorubicin—liver cancer	0.00705	0.0075	CcSEcCtD
Didanosine—Neuropathy—Epirubicin—liver cancer	0.00703	0.00747	CcSEcCtD
Didanosine—Hepatocellular injury—Doxorubicin—liver cancer	0.00692	0.00736	CcSEcCtD
Didanosine—Dry eye—Epirubicin—liver cancer	0.00691	0.00735	CcSEcCtD
Didanosine—Anorexia—Sorafenib—liver cancer	0.00689	0.00732	CcSEcCtD
Didanosine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00658	0.007	CcSEcCtD
Didanosine—Neuropathy—Doxorubicin—liver cancer	0.0065	0.00691	CcSEcCtD
Didanosine—Dry eye—Doxorubicin—liver cancer	0.0064	0.0068	CcSEcCtD
Didanosine—Dyspepsia—Sorafenib—liver cancer	0.00636	0.00676	CcSEcCtD
Didanosine—Decreased appetite—Sorafenib—liver cancer	0.00628	0.00668	CcSEcCtD
Didanosine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00625	0.00664	CcSEcCtD
Didanosine—Diabetes mellitus—Epirubicin—liver cancer	0.00625	0.00664	CcSEcCtD
Didanosine—Hepatic function abnormal—Epirubicin—liver cancer	0.00622	0.00661	CcSEcCtD
Didanosine—Pain—Sorafenib—liver cancer	0.00618	0.00657	CcSEcCtD
Didanosine—Hepatic failure—Epirubicin—liver cancer	0.00605	0.00643	CcSEcCtD
Didanosine—Gastrointestinal pain—Sorafenib—liver cancer	0.00591	0.00628	CcSEcCtD
Didanosine—Renal failure acute—Epirubicin—liver cancer	0.00588	0.00626	CcSEcCtD
Didanosine—Diabetes mellitus—Doxorubicin—liver cancer	0.00578	0.00615	CcSEcCtD
Didanosine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00578	0.00615	CcSEcCtD
Didanosine—Hepatic function abnormal—Doxorubicin—liver cancer	0.00575	0.00612	CcSEcCtD
Didanosine—Body temperature increased—Sorafenib—liver cancer	0.00571	0.00607	CcSEcCtD
Didanosine—Abdominal pain—Sorafenib—liver cancer	0.00571	0.00607	CcSEcCtD
Didanosine—Renal impairment—Epirubicin—liver cancer	0.00571	0.00607	CcSEcCtD
Didanosine—Anaphylactoid reaction—Epirubicin—liver cancer	0.00561	0.00597	CcSEcCtD
Didanosine—Hepatic failure—Doxorubicin—liver cancer	0.00559	0.00595	CcSEcCtD
Didanosine—Hypoglycaemia—Epirubicin—liver cancer	0.00557	0.00592	CcSEcCtD
Didanosine—Renal failure acute—Doxorubicin—liver cancer	0.00544	0.00579	CcSEcCtD
Didanosine—Hypersensitivity—Sorafenib—liver cancer	0.00532	0.00566	CcSEcCtD
Didanosine—Renal impairment—Doxorubicin—liver cancer	0.00528	0.00562	CcSEcCtD
Didanosine—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00519	0.00552	CcSEcCtD
Didanosine—Asthenia—Sorafenib—liver cancer	0.00518	0.00551	CcSEcCtD
Didanosine—Hypoglycaemia—Doxorubicin—liver cancer	0.00515	0.00548	CcSEcCtD
Didanosine—Pruritus—Sorafenib—liver cancer	0.00511	0.00544	CcSEcCtD
Didanosine—Abdominal pain upper—Epirubicin—liver cancer	0.00496	0.00528	CcSEcCtD
Didanosine—Diarrhoea—Sorafenib—liver cancer	0.00494	0.00526	CcSEcCtD
Didanosine—Pancreatitis—Epirubicin—liver cancer	0.0046	0.0049	CcSEcCtD
Didanosine—Vomiting—Sorafenib—liver cancer	0.00459	0.00489	CcSEcCtD
Didanosine—Abdominal pain upper—Doxorubicin—liver cancer	0.00459	0.00488	CcSEcCtD
Didanosine—Rash—Sorafenib—liver cancer	0.00456	0.00484	CcSEcCtD
Didanosine—Dermatitis—Sorafenib—liver cancer	0.00455	0.00484	CcSEcCtD
Didanosine—Headache—Sorafenib—liver cancer	0.00453	0.00481	CcSEcCtD
Didanosine—Nausea—Sorafenib—liver cancer	0.00429	0.00456	CcSEcCtD
Didanosine—Pancreatitis—Doxorubicin—liver cancer	0.00426	0.00453	CcSEcCtD
Didanosine—Hyperglycaemia—Epirubicin—liver cancer	0.00424	0.0045	CcSEcCtD
Didanosine—Neuropathy peripheral—Epirubicin—liver cancer	0.0041	0.00436	CcSEcCtD
Didanosine—Hepatobiliary disease—Epirubicin—liver cancer	0.00396	0.00421	CcSEcCtD
Didanosine—Hyperglycaemia—Doxorubicin—liver cancer	0.00392	0.00417	CcSEcCtD
Didanosine—Agranulocytosis—Epirubicin—liver cancer	0.00391	0.00415	CcSEcCtD
Didanosine—Neuropathy peripheral—Doxorubicin—liver cancer	0.0038	0.00404	CcSEcCtD
Didanosine—Hepatitis—Epirubicin—liver cancer	0.00376	0.004	CcSEcCtD
Didanosine—Hypoaesthesia—Epirubicin—liver cancer	0.00374	0.00398	CcSEcCtD
Didanosine—Hepatobiliary disease—Doxorubicin—liver cancer	0.00366	0.0039	CcSEcCtD
Didanosine—Agranulocytosis—Doxorubicin—liver cancer	0.00361	0.00384	CcSEcCtD
Didanosine—Hepatitis—Doxorubicin—liver cancer	0.00348	0.0037	CcSEcCtD
Didanosine—Hypoaesthesia—Doxorubicin—liver cancer	0.00346	0.00368	CcSEcCtD
Didanosine—Chills—Epirubicin—liver cancer	0.00337	0.00359	CcSEcCtD
Didanosine—Alopecia—Epirubicin—liver cancer	0.00332	0.00353	CcSEcCtD
Didanosine—Flatulence—Epirubicin—liver cancer	0.00322	0.00343	CcSEcCtD
Didanosine—Chills—Doxorubicin—liver cancer	0.00312	0.00332	CcSEcCtD
Didanosine—Alopecia—Doxorubicin—liver cancer	0.00307	0.00327	CcSEcCtD
Didanosine—Anaemia—Epirubicin—liver cancer	0.00302	0.00322	CcSEcCtD
Didanosine—Flatulence—Doxorubicin—liver cancer	0.00298	0.00317	CcSEcCtD
Didanosine—Malaise—Epirubicin—liver cancer	0.00295	0.00314	CcSEcCtD
Didanosine—Leukopenia—Epirubicin—liver cancer	0.00293	0.00311	CcSEcCtD
Didanosine—Anaemia—Doxorubicin—liver cancer	0.0028	0.00298	CcSEcCtD
Didanosine—Myalgia—Epirubicin—liver cancer	0.00279	0.00296	CcSEcCtD
Didanosine—Arthralgia—Epirubicin—liver cancer	0.00279	0.00296	CcSEcCtD
Didanosine—Discomfort—Epirubicin—liver cancer	0.00275	0.00293	CcSEcCtD
Didanosine—Malaise—Doxorubicin—liver cancer	0.00273	0.0029	CcSEcCtD
Didanosine—Dry mouth—Epirubicin—liver cancer	0.00272	0.0029	CcSEcCtD
Didanosine—Leukopenia—Doxorubicin—liver cancer	0.00271	0.00288	CcSEcCtD
Didanosine—Anaphylactic shock—Epirubicin—liver cancer	0.00267	0.00284	CcSEcCtD
Didanosine—Infection—Epirubicin—liver cancer	0.00265	0.00282	CcSEcCtD
Didanosine—Thrombocytopenia—Epirubicin—liver cancer	0.00261	0.00278	CcSEcCtD
Didanosine—Arthralgia—Doxorubicin—liver cancer	0.00258	0.00274	CcSEcCtD
Didanosine—Myalgia—Doxorubicin—liver cancer	0.00258	0.00274	CcSEcCtD
Didanosine—Discomfort—Doxorubicin—liver cancer	0.00255	0.00271	CcSEcCtD
Didanosine—Anorexia—Epirubicin—liver cancer	0.00255	0.00271	CcSEcCtD
Didanosine—Dry mouth—Doxorubicin—liver cancer	0.00252	0.00268	CcSEcCtD
Didanosine—Anaphylactic shock—Doxorubicin—liver cancer	0.00247	0.00263	CcSEcCtD
Didanosine—Infection—Doxorubicin—liver cancer	0.00245	0.00261	CcSEcCtD
Didanosine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00243	0.00259	CcSEcCtD
Didanosine—Thrombocytopenia—Doxorubicin—liver cancer	0.00242	0.00257	CcSEcCtD
Didanosine—Paraesthesia—Epirubicin—liver cancer	0.0024	0.00255	CcSEcCtD
Didanosine—Anorexia—Doxorubicin—liver cancer	0.00235	0.0025	CcSEcCtD
Didanosine—Dyspepsia—Epirubicin—liver cancer	0.00235	0.0025	CcSEcCtD
Didanosine—Decreased appetite—Epirubicin—liver cancer	0.00232	0.00247	CcSEcCtD
Didanosine—Pain—Epirubicin—liver cancer	0.00228	0.00243	CcSEcCtD
Didanosine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00225	0.00239	CcSEcCtD
Didanosine—Paraesthesia—Doxorubicin—liver cancer	0.00222	0.00236	CcSEcCtD
Didanosine—Gastrointestinal pain—Epirubicin—liver cancer	0.00218	0.00232	CcSEcCtD
Didanosine—Dyspepsia—Doxorubicin—liver cancer	0.00217	0.00231	CcSEcCtD
Didanosine—Decreased appetite—Doxorubicin—liver cancer	0.00215	0.00228	CcSEcCtD
Didanosine—Pain—Doxorubicin—liver cancer	0.00211	0.00225	CcSEcCtD
Didanosine—Abdominal pain—Epirubicin—liver cancer	0.00211	0.00224	CcSEcCtD
Didanosine—Body temperature increased—Epirubicin—liver cancer	0.00211	0.00224	CcSEcCtD
Didanosine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00202	0.00215	CcSEcCtD
Didanosine—Hypersensitivity—Epirubicin—liver cancer	0.00197	0.00209	CcSEcCtD
Didanosine—Abdominal pain—Doxorubicin—liver cancer	0.00195	0.00208	CcSEcCtD
Didanosine—Body temperature increased—Doxorubicin—liver cancer	0.00195	0.00208	CcSEcCtD
Didanosine—Asthenia—Epirubicin—liver cancer	0.00192	0.00204	CcSEcCtD
Didanosine—Pruritus—Epirubicin—liver cancer	0.00189	0.00201	CcSEcCtD
Didanosine—Diarrhoea—Epirubicin—liver cancer	0.00183	0.00194	CcSEcCtD
Didanosine—Hypersensitivity—Doxorubicin—liver cancer	0.00182	0.00194	CcSEcCtD
Didanosine—Asthenia—Doxorubicin—liver cancer	0.00177	0.00189	CcSEcCtD
Didanosine—Pruritus—Doxorubicin—liver cancer	0.00175	0.00186	CcSEcCtD
Didanosine—Vomiting—Epirubicin—liver cancer	0.0017	0.00181	CcSEcCtD
Didanosine—Diarrhoea—Doxorubicin—liver cancer	0.00169	0.0018	CcSEcCtD
Didanosine—Rash—Epirubicin—liver cancer	0.00168	0.00179	CcSEcCtD
Didanosine—Dermatitis—Epirubicin—liver cancer	0.00168	0.00179	CcSEcCtD
Didanosine—Headache—Epirubicin—liver cancer	0.00167	0.00178	CcSEcCtD
Didanosine—Nausea—Epirubicin—liver cancer	0.00159	0.00169	CcSEcCtD
Didanosine—Vomiting—Doxorubicin—liver cancer	0.00157	0.00167	CcSEcCtD
Didanosine—Rash—Doxorubicin—liver cancer	0.00156	0.00166	CcSEcCtD
Didanosine—Dermatitis—Doxorubicin—liver cancer	0.00156	0.00166	CcSEcCtD
Didanosine—Headache—Doxorubicin—liver cancer	0.00155	0.00165	CcSEcCtD
Didanosine—Nausea—Doxorubicin—liver cancer	0.00147	0.00156	CcSEcCtD
